From this effort, GPR119 emerged as a promising therapeutic target for the development of orally active, non-peptide, small-molecule agonists to treat type 2 diabetes and obesity (Koole et al., 2010; Yoshida et al., 2010; Semple et al., 2011, 2012; Melancon et al., 2012; Hothersall et al., 2015; Spasov et al., 2017; Fang et al., 2020a). The gene discussed is GPR119; the disease is obesity due to melanocortin 4 receptor deficiency.